Chapter 7 · Module 6

Treatment Strategy, Combination Therapy & Resistant Hypertension

From initiation to intensification — building evidence-based antihypertensive regimens

Combination Therapy — Preferred Pairs & Evidence

Preferred Combinations

Evidence-Based Pairings

CCB + RAAS inhibitor (first choice): ACCOMPLISH — 20% RRR vs RAAS + HCTZ; bidirectional synergy; reduces CCB edema
RAAS inhibitor + thiazide: diuretic activates RAAS → amplifies RAAS inhibitor; RAAS inhibitor blunts hypokalemia
Triple therapy (CCB + RAAS inhibitor + thiazide): standard of care for dual-therapy failures; targets all three BP pathways
CCB + thiazide: additive, non-interacting; when RAAS inhibition is contraindicated (bilateral RAS, prior angioedema)

Combinations to Avoid

Evidence Against These Pairs

ACEi + ARB (dual RAAS blockade): ONTARGET — no cardiovascular benefit over monotherapy; 2× acute kidney injury, more hyperkalemia and hypotension
Non-DHP CCB + beta-blocker: both suppress SA and AV nodes → complete heart block risk — contraindicated
Thiazide + loop diuretic: excessive natriuresis and volume depletion — specialist use only

ACCOMPLISH Trial — Why CCB + RAAS Inhibitor Won

Benazepril + amlodipine vs benazepril + HCTZ: 20% relative risk reduction in cardiovascular events at equivalent achieved blood pressure. The CCB does not just lower blood pressure — it provides a non-renin-angiotensin-aldosterone system vasodilation that is synergistic with renin-angiotensin-aldosterone system inhibition, and the renin-angiotensin-aldosterone system inhibitor reduces the peripheral edema the CCB would otherwise cause.

Resistant Hypertension — Systematic Evaluation

Exclude Pseudo-Resistance

Confirm adherence (urine drug levels if needed) • Perform ambulatory BP monitoring (exclude white coat effect) • Review all medications for BP-raising drugs (NSAIDs, OCP, sympathomimetics, calcineurin inhibitors) • Verify BP technique and cuff size

Optimize the Current Regimen

Switch to chlorthalidone or indapamide (superior 24-h coverage vs HCTZ) • Use loop diuretic if eGFR below 30 mL/min • Ensure all agents at maximally tolerated doses • Address volume overload

Screen for Secondary Causes

Secondary hypertension in 20–40% of true resistant cases • Obstructive sleep apnea: ~80% prevalence in resistant hypertension • Screen: aldosterone-to-renin ratio, plasma metanephrines, renal artery imaging, polysomnography, thyroid-stimulating hormone

Add Fourth-Line Agent — PATHWAY-2

Spironolactone 25–50 mg (first choice): −8.7 mm Hg vs placebo, superior to bisoprolol and doxazosin • Mechanism: volume and aldosterone excess is the near-universal driver in resistant hypertension • If not tolerated: eplerenone (selective MRA) • Alternatives: amiloride, bisoprolol, doxazosin, minoxidil (with mandatory beta-blocker + loop diuretic)

Hypertensive Urgency vs Emergency

The Critical Distinction Is Target Organ Damage — Not the Blood Pressure Number

Urgency vs Emergency Comparison

Feature	Hypertensive Urgency	Hypertensive Emergency
Definition	BP above 180/120 — NO acute target organ damage	BP above 180/120 — WITH acute target organ damage
Symptoms	Asymptomatic or mild headache/anxiety	Encephalopathy, chest pain, dyspnea, neurological deficits
Setting	Outpatient or emergency room	ICU or monitored inpatient setting
Route	Oral agents	Intravenous agents
BP reduction goal	Reduce over 24–48 hours — do NOT lower rapidly	Reduce MAP by no more than 25% in first hour; then 160/100–110 over 2–6 hours
Agents	Clonidine 0.2 mg oral; captopril 25 mg oral; labetalol 200 mg oral	Nicardipine IV; labetalol IV; esmolol IV; clevidipine IV (agent by organ system)
Key caution	Avoid rapid reduction — risk of hypotensive injury to brain and coronary arteries	Aortic dissection: target systolic 100–120 rapidly; ischemic stroke: do NOT lower unless ≥220/120

Compelling Indications — Drug Selection by Comorbidity

When Comorbidity Overrides General Preference Framework

Priority Drug Classes by Compelling Indication

Comorbidity	Priority Drug Classes	Avoid
Heart failure with reduced ejection fraction	ACEi or ARB (or sacubitril-valsartan) + beta-blocker (carvedilol, metoprolol succinate, bisoprolol) + MRA; DHP CCB (amlodipine) safe for BP	Non-DHP CCB (negative inotropy)
Post-myocardial infarction	Beta-blocker + ACEi or ARB; MRA if EF below 40% or diabetes	Non-DHP CCB if left ventricular dysfunction
Diabetes	ACEi or ARB (renoprotection); CCB + low-dose thiazide as additions	High-dose thiazides; non-selective beta-blockers (mask hypoglycemia)
Chronic kidney disease with proteinuria	ACEi or ARB first-line; loop diuretic if eGFR below 30	ACEi + ARB combination; potassium-sparing agents in advanced CKD
Black patients (without above comorbidities)	CCB + thiazide as first-line; ACEi or ARB with compelling indication or as part of combination	ACEi monotherapy (less effective; higher angioedema risk); ARB preferred over ACEi
Atrial fibrillation (rate control)	Beta-blocker or non-DHP CCB (not together)	Non-DHP CCB + beta-blocker (complete heart block)